Hypoxic‐ischemic brain injury in the perinatal period is a major cause of morbidity and
mortality. Presently, there are no proven effective therapies with which to safeguard the …

Hypoxic-ischemic encephalopathy (HIE) is a leading cause of mortality and morbidity during
the perinatal period, and currently no therapeutic drug is available. Minocycline, an …

Minocycline is a second‐generation tetracycline and a potential neuroprotective intervention
following brain injury. However, despite the recognized beneficial effects of minocycline in a …

To investigate whether minocycline provides long‐lasting protection against neonatal
hypoxia–ischemia‐induced brain injury and neurobehavioral deficits, minocycline was …

An increase in the number of activated microglia in the brain is a key feature of
neuroinflammation after a hypoxic–ischemic insult to the preterm neonate and can …

The neuroprotective effects of minocycline–which is broadly protective in neurologic-disease
models featuring cell death and is being evaluated in clinical trials–were investigated both in …

The incidence of neonatal stroke is high and currently there are no strategies to protect the
neonatal brain from stroke or reduce the sequelae. Agents capable of modifying …

Minocycline is currently under development as a neuroprotective agent in many different
brain diseases. In more than a dozen experimental investigations in various models of brain …

Background Minocycline, a second-generation tetracycline with anti-inflammatory and anti-
apoptotic properties, has been shown to promote therapeutic benefits in experimental …

The role of minocycline in preventing white matter injury, in particular the injury to
developing oligodendrocytes was examined in a neonatal rat model of hypoxia–ischemia …